SAB Biotherapeutics

Yahoo Finance • 28 days ago

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in an outpatient setting for... Full story

Yahoo Finance • last month

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases,... Full story

Yahoo Finance • 2 months ago

SAB Biotherapeutics reports Q3 results

* SAB Biotherapeutics press release [https://seekingalpha.com/pr/20307525-sab-bio-reports-third-quarter-financial-results-and-recent-business-highlights] (SABS [https://seekingalpha.com/symbol/SABS]): net income of $45.4 million and a ne... Full story

Yahoo Finance • 2 months ago

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Initiated registrational Phase 2b SAFEGUARD trial of SAB-142 in new-onset, Stage 3 autoimmune T1D patients Multiple SAFEGUARD trial sites activated; on-track to dose first patient by year-end Recent data presented at EASD and IPSAD provide... Full story

Yahoo Finance • 4 months ago

SAB BIO Highlights Data in Multiple Presentations at EASD

-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142 in new-onset Stage 3 autoimmune T1D patients, EASD provided an opportunity to connect with many T1D thought leaders that will participate in the study- -Data in multiple SAB prese... Full story

Yahoo Finance • 4 months ago

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a multi-specific human an... Full story

Yahoo Finance • 4 months ago

SAB Biotherapeutics files to sell 250M shares of common stock for holders

* SAB Biotherapeutics (NASDAQ:SABS [https://seekingalpha.com/symbol/SABS]) filed to sell 250M shares of common stock for holders. * Filing [https://seekingalpha.com/filing/10374430] MORE ON SAB BIOTHERAPEUTICS * Seeking Alpha’s... Full story

Yahoo Finance • 5 months ago

Chardan Capital lowers SAB Biotherapeutics stock price target to $12 from $20

Investing.com - Chardan Capital Markets has lowered its price target on SAB Biotherapeutics (NASDAQ:SABS) stock to $12.00 from $20.00 while maintaining a Buy rating following the company’s second-quarter financial results. According to Inv... Full story

Yahoo Finance • 6 months ago

SAB Biotherapeutics stock price target raised to $14 from $12 at Oppenheimer

Investing.com - Oppenheimer has raised its price target on SAB Biotherapeutics (NASDAQ:SABS) to $14.00 from $12.00 while maintaining an Outperform rating on the stock. The new target represents significant upside from the current price of... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

First subject has been dosed in the first-in-man Phase 1 clinical study of SAB-142, the first fully-human anti-thymocyte immunoglobulin (ATG) SAB-142 directly and specifically targets multiple immune cells involved in the destruction of i... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte immunoglobulin (hIgG)... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes

Funding will support development of SAB-142, a potential disease-modifying therapy for type 1 diabetes and other autoimmune conditions Participating investors include Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW, and th... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates

Raises combined $67.1M in private placement plus Tranche warrant exercise with syndicate of leading investors Received approval by the Human Research Ethics Committee (HREC) to commence a First-in-Human Phase 1 clinical trial investigatin... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference

SIOUX FALLS, S.D., Nov. 09, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglob... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer

SIOUX FALLS, S.D., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage biopharmaceutical company with a nove... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes

Australian Human Research Ethics Committee (HREC) grants approval for SAB to begin first-in-human Phase 1 clinical study of SAB-142, the first fully human anti-thymocyte immunoglobulin (ATG) SAB-142 directly targets multiple immune cells... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors

SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) f... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Announces Private Placement of up to $130 Million to Advance Development of Lead Drug Candidate for Type 1 Diabetes

Funding to support clinical advancement of SAB-142, a potential disease-modifying treatment Financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, an... Full story

Yahoo Finance • 2 years ago

SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results

SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human... Full story

Yahoo Finance • 3 years ago

SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023

SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatme... Full story